Jeffery Ward, an oncologist at Swedish Cancer Institute and chair of the ASCO payment reform working group, said the task force considered alternatives to buy-and-bill but couldn't arrive at a solution.

He also said concerns that buy-and-bill leads oncologists to favor expensive IV drugs are exaggerated. Indeed, he said the ASP+6% method provides "an incentive to look for the lowest-cost drug."